The GioTag study is a real-world retrospective, observational and unblinded study which examined the impact of treatment with Giotrif/Gilotrif (afatinib) followed by osimertinib in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
The GioTag study previously provided only 2 years and 2.5 years OS rates. Now, a subsequent analysis assessed updated data from a sub-set of patients with available electronic health records (from the U.S). The use of electronic data, which facilitated rapid analysis, represented the first step of a two-stage process.
After a median follow-up of 30.3 months, median overall survival was almost three and a half years (41.3 months) in patients with acquired EGFR T790M-positive NSCLC treated in a real-world clinical setting, and the updated two-year OS rate was 80%.
OS is particularly promising in patients with Del19-positive tumours at the onset of afatinib treatment. In these patients, median OS was 45.7 months and the two-year OS rate was 82%.
Updated median time on treatment for sequential afatinib and osimertinib was 28.1 months overall, and 30.6 months in patients with Del19-positive tumours.
Median time on osimertinib treatment following treatment with afatinib was 15.6 months and 16.4 month for Del19 mutations.
The observational GioTag study provides data on a broad, real-world population of patients. 15.3% had a poor performance status of ECOG PS of ≥2 and 10.3% had stable brain metastases, ordinarily criteria which would preclude these patients from participation in clinical trials.
More on the observational GioTag study can be found here.
This interim analysis is the first of a two-step process. A final analysis is planned for early 2020 which will include updated data from Asian and European countries.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib